126 related articles for article (PubMed ID: 37962020)
21. Pregnancy-specific glycoprotein 9 (PSG9), a driver for colorectal cancer, enhances angiogenesis via activation of SMAD4.
Yang L; Hu S; Tan J; Zhang X; Yuan W; Wang Q; Xu L; Liu J; Liu Z; Jia Y; Huang X
Oncotarget; 2016 Sep; 7(38):61562-61574. PubMed ID: 27528036
[TBL] [Abstract][Full Text] [Related]
22. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
Peng WX; Huang JG; Yang L; Gong AH; Mo YY
Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
[TBL] [Abstract][Full Text] [Related]
23. DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
Png CW; Weerasooriya M; Guo J; James SJ; Poh HM; Osato M; Flavell RA; Dong C; Yang H; Zhang Y
Oncogene; 2016 Jan; 35(2):206-17. PubMed ID: 25772234
[TBL] [Abstract][Full Text] [Related]
24. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK.
Voorneveld PW; Kodach LL; Jacobs RJ; Liv N; Zonnevylle AC; Hoogenboom JP; Biemond I; Verspaget HW; Hommes DW; de Rooij K; van Noesel CJ; Morreau H; van Wezel T; Offerhaus GJ; van den Brink GR; Peppelenbosch MP; Ten Dijke P; Hardwick JC
Gastroenterology; 2014 Jul; 147(1):196-208.e13. PubMed ID: 24704720
[TBL] [Abstract][Full Text] [Related]
25. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
Itatani Y; Kawada K; Fujishita T; Kakizaki F; Hirai H; Matsumoto T; Iwamoto M; Inamoto S; Hatano E; Hasegawa S; Maekawa T; Uemoto S; Sakai Y; Taketo MM
Gastroenterology; 2013 Nov; 145(5):1064-1075.e11. PubMed ID: 23891973
[TBL] [Abstract][Full Text] [Related]
26. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
27. Loss of Setd2 associates with aberrant microRNA expression and contributes to inflammatory bowel disease progression in mice.
Chen Y; Liu M; Wang W; Cai W; Song W; Li L; Lin GN
Genomics; 2021 Jul; 113(4):2441-2454. PubMed ID: 34052319
[TBL] [Abstract][Full Text] [Related]
28. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
29. Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer.
Kang JH; Jang JE; Mishra SK; Lee HJ; Nho CW; Shin D; Jin M; Kim MK; Choi C; Oh SH
J Ethnopharmacol; 2015 Sep; 173():303-12. PubMed ID: 26210065
[TBL] [Abstract][Full Text] [Related]
30. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm.
Zhang Y; Xie S; Zhou Y; Xie Y; Liu P; Sun M; Xiao H; Jin Y; Sun X; Chen Z; Huang Q; Chen S
Cell Rep; 2014 Sep; 8(6):1989-2002. PubMed ID: 25242323
[TBL] [Abstract][Full Text] [Related]
31. RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.
Zhang M; Zhao S; Tan C; Gu Y; He X; Du X; Li D; Wei P
J Exp Clin Cancer Res; 2021 Jun; 40(1):200. PubMed ID: 34154626
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
33. Mice with dysfunctional TGF-β signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU.
Wang Z; Hopson LM; Singleton SS; Yang X; Jogunoori W; Mazumder R; Obias V; Lin P; Nguyen BN; Yao M; Miller L; White J; Rao S; Mishra L
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166179. PubMed ID: 34082069
[TBL] [Abstract][Full Text] [Related]
34. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
[TBL] [Abstract][Full Text] [Related]
35. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Iglesias M; Frontelo P; Gamallo C; Quintanilla M
Oncogene; 2000 Aug; 19(36):4134-45. PubMed ID: 10962574
[TBL] [Abstract][Full Text] [Related]
36. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Zhang B; Zhang B; Chen X; Bae S; Singh K; Washington MK; Datta PK
Br J Cancer; 2014 Feb; 110(4):946-57. PubMed ID: 24384683
[TBL] [Abstract][Full Text] [Related]
37. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.
Voorneveld PW; Kodach LL; Jacobs RJ; van Noesel CJ; Peppelenbosch MP; Korkmaz KS; Molendijk I; Dekker E; Morreau H; van Pelt GW; Tollenaar RA; Mesker W; Hawinkels LJ; Paauwe M; Verspaget HW; Geraets DT; Hommes DW; Offerhaus GJ; van den Brink GR; Ten Dijke P; Hardwick JC
Br J Cancer; 2015 Jan; 112(1):122-30. PubMed ID: 25393365
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
39. VPS33B negatively modulated by nicotine functions as a tumor suppressor in colorectal cancer.
Chen Y; Liu Z; Wang H; Tang Z; Liu Y; Liang Z; Deng X; Zhao M; Fu Q; Li L; Cai H; Xie W; Fang W
Int J Cancer; 2020 Jan; 146(2):496-509. PubMed ID: 31125123
[TBL] [Abstract][Full Text] [Related]
40. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
